Previous close | 0.0500 |
Open | 0.0500 |
Bid | 0.0000 |
Ask | 0.4700 |
Strike | 185.00 |
Expiry date | 2024-04-26 |
Day's range | 0.0500 - 0.0500 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Generic and biosimilar manufacturer Sandoz AG (OTC:SDZNY) (OTC:SDZXF) reached an agreement on Tuesday with Amgen Inc (NASDAQ:AMGN) to resolve all patent litigation related to its U.S. denosumab biosimilars. Sandoz said in a statement that the agreement clears the way for the launch of denosumab biosimilars Jubbonti and Wyost on May 31, 2025, or earlier under certain circumstances. “The terms of the agreement will not impact our previously disclosed 2024 guidance,” Sandoz said. Sandoz received FD
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
Swiss generic and biosimilar manufacturer Sandoz said on Tuesday it had reached an agreement with U.S. drugmaker Amgen resolving all patent litigation related to its U.S. denosumab biosimilars. The agreement clears the way for the launch of denosumab biosimilars Jubbonti and Wyost on May 31, 2025, or earlier under certain circumstances, Sandoz said in a statement. "The terms of the agreement will not impact our previously disclosed 2024 guidance," Sandoz said.